CN101505773A - 用于治疗眼病的药物 - Google Patents
用于治疗眼病的药物 Download PDFInfo
- Publication number
- CN101505773A CN101505773A CNA2006800557004A CN200680055700A CN101505773A CN 101505773 A CN101505773 A CN 101505773A CN A2006800557004 A CNA2006800557004 A CN A2006800557004A CN 200680055700 A CN200680055700 A CN 200680055700A CN 101505773 A CN101505773 A CN 101505773A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- reagent
- berry
- agent
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000030533 eye disease Diseases 0.000 title claims abstract description 11
- 240000000851 Vaccinium corymbosum Species 0.000 claims abstract description 11
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims abstract description 11
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 11
- 235000021014 blueberries Nutrition 0.000 claims abstract description 11
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 10
- 239000011720 vitamin B Substances 0.000 claims abstract description 10
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims abstract description 7
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 7
- 239000011648 beta-carotene Substances 0.000 claims abstract description 7
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 7
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 7
- 229960002747 betacarotene Drugs 0.000 claims abstract description 7
- XCGZWJIXHMSSQC-UHFFFAOYSA-N dihydroquercetin Natural products OC1=CC2OC(=C(O)C(=O)C2C(O)=C1)c1ccc(O)c(O)c1 XCGZWJIXHMSSQC-UHFFFAOYSA-N 0.000 claims abstract description 7
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000011701 zinc Substances 0.000 claims abstract description 5
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 5
- 235000016804 zinc Nutrition 0.000 claims abstract description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 229930003270 Vitamin B Natural products 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 210000002189 macula lutea Anatomy 0.000 claims description 8
- 235000021028 berry Nutrition 0.000 claims description 6
- 230000004438 eyesight Effects 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 208000035719 Maculopathy Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 208000003464 asthenopia Diseases 0.000 claims description 4
- 230000003203 everyday effect Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 208000001140 Night Blindness Diseases 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- 229930003451 Vitamin B1 Natural products 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229930003471 Vitamin B2 Natural products 0.000 claims description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 229960003495 thiamine Drugs 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- 235000010374 vitamin B1 Nutrition 0.000 claims description 2
- 239000011691 vitamin B1 Substances 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019164 vitamin B2 Nutrition 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 14
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 239000000306 component Substances 0.000 abstract description 4
- 235000013619 trace mineral Nutrition 0.000 abstract description 4
- 239000011573 trace mineral Substances 0.000 abstract description 4
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 abstract description 4
- 238000001228 spectrum Methods 0.000 abstract description 3
- 229940088594 vitamin Drugs 0.000 abstract description 3
- 229930003231 vitamin Natural products 0.000 abstract description 3
- 235000013343 vitamin Nutrition 0.000 abstract description 3
- 239000011782 vitamin Substances 0.000 abstract description 3
- 230000002757 inflammatory effect Effects 0.000 abstract description 2
- 235000012680 lutein Nutrition 0.000 abstract description 2
- 229960005375 lutein Drugs 0.000 abstract description 2
- 239000001656 lutein Substances 0.000 abstract description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 abstract description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 abstract description 2
- -1 selexen Chemical compound 0.000 abstract description 2
- 235000013311 vegetables Nutrition 0.000 abstract description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 abstract description 2
- 230000002009 allergenic effect Effects 0.000 abstract 1
- 230000000622 irritating effect Effects 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001256 tonic effect Effects 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000654 additive Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 3
- 238000001720 action spectrum Methods 0.000 description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 3
- 229960004555 rutoside Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 2
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 2
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 108010084210 citrin Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 2
- 235000010930 zeaxanthin Nutrition 0.000 description 2
- 239000001775 zeaxanthin Substances 0.000 description 2
- 229940043269 zeaxanthin Drugs 0.000 description 2
- USMZEYPOTJAYPT-LRROQMAJSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 USMZEYPOTJAYPT-LRROQMAJSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000002201 avitaminosis Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940055416 blueberry extract Drugs 0.000 description 1
- 235000019216 blueberry extract Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及化学和制药工业，特别是涉及开发以植物组分、维生素、和微量元素为基础的具有宽作用谱的眼科用试剂。用于治疗眼病的本发明的试剂包括冻干的蓝莓、二氢槲皮素、β－胡萝卜素、selexen、叶黄素、维生素B1、B2、B6、和B12、和锌。具有宽的作用谱的所述试剂表现出修补、滋补和再生的作用，其没有任何刺激性、变应原性、炎性或其它不希望的作用，并且其避免了与眼睛表面的机械接触。
Description
技术领域
本发明涉及化学和制药工业，特别是涉及开发以植物组分、维生素、和微量元素为基础的具有宽作用谱的眼科用试剂。
背景技术
用于治疗某些眼病的医用试剂通常以供外用的滴剂或膏剂的形式使用是已知的。
以褐藻提取物为基础的用于治疗各种眼病的眼科用医用试剂是已知的(俄罗斯专利2104679，A 61 F 9/00)。
另外已知的是用于治疗和预防眼病的生物学活性的食品添加剂，包括胡萝卜汁、蜂王浆、蓝莓、抗坏血酸、芦丁、维生素E、烟酸、和作为助剂的糖、淀粉、和硬脂酸钙(俄罗斯专利21097258，A 61 K35/78)。
对于患有糖尿病的患者具有治疗和预防活性的植物浓缩物是已知的，所述浓缩物包括槲皮素、二氢槲皮素、芦丁或ascorutin作为生物学活性成分。所述浓缩物另外包括药用植物和肉浓缩物或鸡浓缩物或植物浓缩物。治疗和预防性植物浓缩物可用于各种年龄的患者的临床或不卧床的病况，并且对于人类来说，其将预防和温和的治疗组合起来(俄罗斯专利2123350，A 61 K 35/78)。
另外已知的是用于预防视力障碍和进行视力校正的生物学活性的食品添加剂，所述添加剂包括蓝莓、干的银杏提取物、干的银杏叶的细粉末、硬脂酸镁和/或硬脂酸钙、淀粉和/或微晶纤维素。所述添加剂对视觉器官具有毛细管增强和抗炎作用，抑制自由基对视觉器官的不利影响并且改善总体的健康(俄罗斯专利2270583，A 23 L 1/30)。
以干的五味子属(Schizandra)浆果的水煎剂为基础的用于增加视敏度的药物是已知的，其用于外用放置在结膜囊(conjunctival sacs)中或者通过电泳对眼组织施用(苏联发明171981，A 61 K 35/78)。
蓝莓的叶和浆果用于医疗的用途是已知的。
已经证明使用蓝莓不仅对人类具有广的作用谱而且还改善视敏度，扩展视野和减少眼睛疲劳，而对眼睛表面没有作用或对者患者的心理没有创伤(Gaetan Zheyl，＂Extrakt tcherniki izrenie＂(＂Blue-berry extract and vision＂)，TASS，Byulleteninostrannoy nautchno-tekhnitcheskoy informatsii TASS，1964，72(962)，1964)。
另外，已经确定了在蓝莓中包含的黄酮类化合物(芦丁、槲皮素、维生素P)增强血管壁并且调节其渗透性。
此外，已知含维生素P的制备物可用于治疗维生素缺乏症、视网膜出血、许兰-亨诺病、和用于角膜亲神经过程的恢复。
上述的医用试剂涉及视觉功能的改善。然而，将它们以膏剂、薄膜或滴剂的形式使用涉及与眼睛表面的机械接触以及使其受伤。此外，每种已知的试剂都表现出特异性定向的作用。
同时，有这样的情况，即，其中眼睛表面的过度使用、其刺激性以及患者的相应的心理学创伤是非常不受欢迎的，但是对视觉功能的作用是必需的。在此情况下，使用片剂、胶囊、茶类或提取物形式的口服内部给药的医用试剂。
本发明最接近的技术方案是生物学活性的添加剂(BAA)“Okulist”，其包括冻干的蓝莓浆果、β-胡萝卜素、二氢槲皮素和selexen(TU 9197-028-17664661-05 CEZ 3？？.99.29.003，July 26，2005)。这种添加剂被推荐用于视网膜病、夜盲症、眼睛疲劳、青光眼、和白内障的情况中。
所述制备物提供了优于其它已知制备物的许多优点。其内部使用避免了对眼睛表面的创伤。然而，其还表现出作用的定向特征并且没有延长的作用。
发明内容
本发明的目的是通过开发植物组分、维生素、和微量元素的平衡的复合物提供用于治疗眼病的宽的作用谱的试剂。
所述技术效果来自于本发明试剂具有修补作用、滋补(强壮)作用和再生作用，其在生态学方面是清洁的并且不表现出任何刺激性、变应原性、炎性或其它不希望的作用，其避免了与眼睛表面的机械接触并且增加了治疗作用，并且其还可以用于黄斑(黄斑营养不良)和视网膜的病理学的支持疗法。
优选实施方式
所述目的是通过本发明的用于治疗眼病的试剂来实现的，所述试剂包括冻干的蓝莓、二氢槲皮素、β-胡萝卜素和selexen，以及另外的叶黄素、维生素B1、B2、B6、和B12、和锌，每个胶囊含如下数量的如下成分，所述量以mg表示：
冻干的蓝莓浆果 282.7
二氢槲皮素 17.0
β-胡萝卜素 0.23
selexen 0.07
叶黄素 0.75-20.0
维生素B1 0.255-10.2
维生素B2 0.3-12.0
维生素B6 0.3-12.0
维生素B12 0.45-18.0μg
锌 1.8-80.0。
所述试剂可在视网膜病、夜盲症、眼睛疲劳、青光眼、和白内障的情况中用于改善视力。
所述试剂可用作药物，用于黄斑(黄斑营养不良)和视网膜的病理学的支持疗法。
本发明的试剂暂时被称为“Okulist-kompleks”。
“Okulist-komplex”是通过将所示量的成分混合并且将混合物填充在胶囊中得到的。
用于预防上述疾病的剂量是在进食期间的每日三次，每次一个胶囊。
支持疗法的剂量是进食期间的每日三次，每次两个胶囊。
已经在俄罗斯联邦(Russian Federation)的国防部(Ministry ofDefense)的中央军临床医院(Central Military Clinical Hospital)、在Moscow的用于眼病“Gelmgolts”的科学和研究所(Science andResearch Institute for Eye Diseases＂Gelmgolts＂)、以及在Morozovsk市的临床儿科医院(Clinical Pediatric Hospital)对志愿者进行的临床研究。
临床研究的结果得出以下结论：
-在给予所述药物期间没有一个病例观察到过敏性反应或者不希望的现象；
-在治疗期间观察到药物的好的耐受性；
-与BAA“Okulist”相比较，在反复给予“Okulist-kompleks”的情况中，观察到积极的增强作用。
视网膜中心部分的主要损坏原因是日光的作用，特别是其光谱中的最具攻击性的短波(UV-、紫色和蓝色)部分。人眼具有预防过量太阳辐射的若干水平的防护措施，即，收缩瞳孔的有颜色的虹膜、以及黄斑，黄斑是位于视网膜的最敏感部分正前方的天然射线过滤器。所述黄斑的颜色和光吸收性能是由选择性地在其中积聚的两种天然的类胡萝卜素来保证的，即，叶黄素和玉米黄素。
人类不能合成这些物质，必需从外界提供。
这种情况的解决方案是增加具有高的叶黄素和玉米黄素含量的蔬菜(胡萝卜、菠菜、谷物、番茄、豆类、金盏花、等等)的用量，以及开发包含这些物质的药物。
由于治疗黄斑视网膜病的方法是未知的，目前，这些预防性措施是对抗年龄依赖性视力损失的唯一可靠方法。
最近，出现了得自万寿菊的包含叶黄素的生物学活性添加剂。研究已经确认，叶黄素良好地被吸附和储存在黄斑中，允许通过将叶黄素作为添加剂给药来增加其密度(J.A.Mares-Perlman等人，Am.J.Epidemiol.-2001，vol.62，p.1448-1461)。
即使叶黄素对于预防黄斑营养不良是重要的，它还对于为生物(特别是属于危险组的患者)提供另外的微量营养素(尤其是抗氧化剂)来说是非常重要的。
工业实用性
对预防由自由基的活化和过氧化过程引起的眼病(即，白内障和黄斑变性)的数据分析确认了本发明的复合物提供好的治疗作用。与明确地控制单线态氧的中和以免黄斑变性的叶黄素一起，物质(植物组分、B维生素、β-胡萝卜素、微量元素)的平衡复合物支持正常的视力，这些物质补充和增加彼此的作用。
Claims (5)
1.用于治疗眼病的试剂，包括冻干的蓝莓浆果、二氢槲皮素、β-胡萝卜素和selexen，特征在于其另外包括叶黄素、维生素B1、B2、B6、和B12、和锌，每个胶囊含如下数量的如下成分，所述量mg表示：
冻干的蓝莓浆果 282.7
二氢槲皮素 17.0
β-胡萝卜素 0.23
selexen 0.07
叶黄素 0.75-20.0
维生素B1 0.255-10.2
维生素B2 0.3-12.0
维生素B6 0.3-12.0
维生素B12 0.45-18.0μg
锌 1.8-80.0。
2.权利要求1的试剂，其特征在于其可以在视网膜病、夜盲症、眼睛疲劳、青光眼、和白内障的情况中用于改善视力。
3.权利要求1的试剂，其特征在于其可以用于黄斑(黄斑营养不良)和视网膜的病理学的支持疗法。
4.权利要求2或3的试剂，其特征在于对于所述疾病的预防来说，剂量为进食期间的每日三次，每次一个胶囊。
5.权利要求2或3的试剂，其特征在于在支持疗法中，剂量为进食期间的每日三次，每次两个胶囊。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2006131038 | 2006-08-29 | ||
| RU2006131038/15A RU2315612C1 (ru) | 2006-08-29 | 2006-08-29 | Средство для лечения заболеваний глаз |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101505773A true CN101505773A (zh) | 2009-08-12 |
Family
ID=39109937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006800557004A Pending CN101505773A (zh) | 2006-08-29 | 2006-11-27 | 用于治疗眼病的药物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090297625A1 (zh) |
| EP (1) | EP2060264A4 (zh) |
| JP (1) | JP2010502597A (zh) |
| CN (1) | CN101505773A (zh) |
| CA (1) | CA2662114A1 (zh) |
| RU (1) | RU2315612C1 (zh) |
| WO (1) | WO2008026962A1 (zh) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251927A (zh) * | 2013-04-11 | 2013-08-21 | 深圳市百汇生物技术有限公司 | 含越橘提取物的组合物 |
| CN103349192A (zh) * | 2013-02-01 | 2013-10-16 | 福建省汉堂生物制药股份有限公司 | 一种护眼冲剂及其制备方法 |
| CN104921123A (zh) * | 2015-06-19 | 2015-09-23 | 北京元莱健康管理有限公司 | 一种促进幼儿眼脑发育的组合物及其制备方法 |
| CN105011154A (zh) * | 2015-06-19 | 2015-11-04 | 北京元莱健康管理有限公司 | 一种缓解青少年视疲劳促进记忆力的组合物及其制备方法 |
| CN106174510A (zh) * | 2016-07-22 | 2016-12-07 | 柳州名品科技有限公司 | 一种改善老花眼症状的保健食品 |
| CN107530319A (zh) * | 2015-02-26 | 2018-01-02 | 春天生技药品股份有限公司 | 用于治疗眼疾的化合物 |
| WO2020152527A1 (en) * | 2019-01-24 | 2020-07-30 | Ravi Lakkineni | Ophthalmic pharmaceutical compositions based on vitamins, amino acids and minerals for treating immature cataract |
| CN112791113A (zh) * | 2020-12-29 | 2021-05-14 | 济南瑞隆安生物技术有限公司 | 一种缓解眼疲劳的蓝莓叶黄素滴眼液及其制备方法 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008029460A1 (de) * | 2008-06-20 | 2009-12-31 | Otkrytoe Aktsionernoe Obschestvo Zavod Ekologicheskoy Tekhniki I Ekopitaniya 'diod' | Taxifolinderivate zur Prophylaxe und Behandlung von neurologischen und psychiatrischen Störungen des zentralen Nervensystems |
| RU2560077C1 (ru) * | 2014-05-20 | 2015-08-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Иркутский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Растительный сбор "эуфразин", обладающий антиоксидантной и ноотропной активностью |
| SG11201704161YA (en) | 2014-11-25 | 2017-06-29 | Abbott Lab | Method of improving visual processing, visual acuity, or both by administering compositions comprising rrr-alpha-tocopherol and carotenoid to infants |
| JP6646368B2 (ja) * | 2015-06-25 | 2020-02-14 | 株式会社東洋新薬 | 網膜保護組成物 |
| CH712067A2 (it) * | 2016-01-28 | 2017-07-31 | Pinelli Roberto | Integratore nutrizionale per il mantenimento dello stato di salute dell'occhio. |
| JP6866354B2 (ja) * | 2016-04-18 | 2021-04-28 | サントリーホールディングス株式会社 | Ｔｉｅ２活性化用組成物 |
| CN107595911A (zh) * | 2017-09-27 | 2018-01-19 | 广州市范乐医药科技有限公司 | 一种改善视力的叶黄素胶囊 |
| IT201800007592A1 (it) * | 2018-07-27 | 2020-01-27 | Roberto Pinelli | Integratore nutrizionale comprendente Emblica officinalis |
| JP6736137B2 (ja) * | 2019-07-11 | 2020-08-05 | 株式会社東洋新薬 | 網膜保護組成物 |
| JP7005043B2 (ja) * | 2020-07-08 | 2022-02-10 | 株式会社東洋新薬 | 網膜保護組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2104679C1 (ru) | 1996-12-27 | 1998-02-20 | Святослав Николаевич Федоров | Офтальмологическое лекарственное средство |
| RU2123350C1 (ru) | 1997-12-30 | 1998-12-20 | Борщев Александр Николаевич | Фитоконцентрат лечебно-профилактического действия для лиц с заболеванием сахарным диабетом |
| US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
| ES2258426T3 (es) * | 2000-06-16 | 2006-09-01 | Matthias Dr. Med. Rath | Composicion para la prevencion de enfermedades de los musculos lisos que comprenden ascorbato, arginina y magnesio. |
| RU2201179C2 (ru) * | 2001-01-15 | 2003-03-27 | Туманова Анна Леоновна | Способ лечения диабетических ретинопатий |
| RU2197258C1 (ru) | 2001-05-21 | 2003-01-27 | Общество с ограниченной ответственностью Фирма "ЭЙКОСЪ" | Биологически активная пищевая добавка для лечения и профилактики глазных заболеваний "глазные" |
| RU2270583C2 (ru) | 2001-12-10 | 2006-02-27 | Закрытое акционерное общество "Эвалар" | Биологически активная добавка к пище для профилактики нарушений и коррекции зрения |
| US7083813B2 (en) * | 2002-11-06 | 2006-08-01 | The Quigley Corporation | Methods for the treatment of peripheral neural and vascular ailments |
| US7282225B1 (en) * | 2006-09-27 | 2007-10-16 | Occular Technologies, Inc. | Composition and methods for improving retinal health |
-
2006
- 2006-08-29 RU RU2006131038/15A patent/RU2315612C1/ru active
- 2006-11-27 US US12/439,366 patent/US20090297625A1/en not_active Abandoned
- 2006-11-27 WO PCT/RU2006/000629 patent/WO2008026962A1/ru active Application Filing
- 2006-11-27 EP EP06849631A patent/EP2060264A4/en not_active Withdrawn
- 2006-11-27 CN CNA2006800557004A patent/CN101505773A/zh active Pending
- 2006-11-27 CA CA002662114A patent/CA2662114A1/en not_active Abandoned
- 2006-11-27 JP JP2009526563A patent/JP2010502597A/ja not_active Withdrawn
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103349192A (zh) * | 2013-02-01 | 2013-10-16 | 福建省汉堂生物制药股份有限公司 | 一种护眼冲剂及其制备方法 |
| CN103251927A (zh) * | 2013-04-11 | 2013-08-21 | 深圳市百汇生物技术有限公司 | 含越橘提取物的组合物 |
| CN107530319A (zh) * | 2015-02-26 | 2018-01-02 | 春天生技药品股份有限公司 | 用于治疗眼疾的化合物 |
| CN107530319B (zh) * | 2015-02-26 | 2023-01-24 | 彦臣生技药品股份有限公司 | 用于治疗眼疾的化合物 |
| CN104921123A (zh) * | 2015-06-19 | 2015-09-23 | 北京元莱健康管理有限公司 | 一种促进幼儿眼脑发育的组合物及其制备方法 |
| CN105011154A (zh) * | 2015-06-19 | 2015-11-04 | 北京元莱健康管理有限公司 | 一种缓解青少年视疲劳促进记忆力的组合物及其制备方法 |
| CN106174510A (zh) * | 2016-07-22 | 2016-12-07 | 柳州名品科技有限公司 | 一种改善老花眼症状的保健食品 |
| WO2020152527A1 (en) * | 2019-01-24 | 2020-07-30 | Ravi Lakkineni | Ophthalmic pharmaceutical compositions based on vitamins, amino acids and minerals for treating immature cataract |
| CN112791113A (zh) * | 2020-12-29 | 2021-05-14 | 济南瑞隆安生物技术有限公司 | 一种缓解眼疲劳的蓝莓叶黄素滴眼液及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20090297625A1 (en) | 2009-12-03 |
| EP2060264A1 (en) | 2009-05-20 |
| JP2010502597A (ja) | 2010-01-28 |
| CA2662114A1 (en) | 2008-03-06 |
| EP2060264A4 (en) | 2012-11-14 |
| WO2008026962A1 (fr) | 2008-03-06 |
| RU2315612C1 (ru) | 2008-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101505773A (zh) | 用于治疗眼病的药物 | |
| CN103355555A (zh) | 一种蛋鸡产蛋高峰期饲料及其制备方法 | |
| CN104435763B (zh) | 一种治疗眼病的药物 | |
| CN101991111B (zh) | 一种可缓解视疲劳的药品或者保健食品 | |
| CN104224890A (zh) | 一种叶黄素软胶囊及其制备方法 | |
| CN106038612A (zh) | 一种保护眼睛视力的药物组合物及其制备方法和应用 | |
| CN104474018A (zh) | 一种缓解视疲劳的保健软胶囊 | |
| CN103316032B (zh) | 含有羟基酪醇的组合物及其应用 | |
| CN105232907A (zh) | 一种补肾壮阳饮料及其制备方法 | |
| CN110354204A (zh) | 一种具有明目功效的组合物及其制备、应用方法 | |
| CN104257727A (zh) | 缓解视疲劳软胶囊及加工方法 | |
| CN106539083A (zh) | 一种用于预防和治疗糖尿病视网膜病变、缓解视力疲劳的组合物 | |
| CN101416741A (zh) | 一种用于缓解视疲劳的保健食品 | |
| CN106692187A (zh) | 一种用于改善明视持久度、保护眼睛健康的组合物 | |
| CN105106286A (zh) | 一种护眼明目的保健品 | |
| CN105106318A (zh) | 一种治疗干眼症的中药组合物及其制备方法 | |
| CN101229287A (zh) | 多元茄红素防治眼疾胶囊及其制备方法 | |
| CN108888682A (zh) | 一种明目护眼组合物 | |
| CN106692259A (zh) | 一种用于改善眩光刺激的组合物 | |
| CN109865016A (zh) | 一种治疗干眼症的药物组合物及其制备方法和用途 | |
| CN102150860A (zh) | 一种用于缓解视疲劳和辅助改善记忆的组合物 | |
| CN109260397A (zh) | 一种治疗眼底血管性疾病的中药组合物 | |
| CN106072584A (zh) | 一种叶黄素酯和沙棘油复合型食用保健品 | |
| CN109875048A (zh) | 护眼组合物及其应用 | |
| CN109432191A (zh) | 一种缓解眼疲劳的眼贴及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20090812 |